- Open Access
Correlation between the functional impairment of bone marrow-derived circulating progenitor cells and the extend of coronary artery disease
- Ilkay Bozdag-Turan†1Email author,
- R Goekmen Turan†1Email author,
- Lylia Paranskaya†1,
- Nicole S Arsoy1,
- C Hakan Turan1,
- Ibrahim Akin1,
- Stephan Kische1,
- Jasmin Ortak1,
- H Schneider1,
- S Ludovicy1,
- Tina Hermann1,
- Giuseppe D’Ancona1,
- Serkan Durdu2,
- A Ruchan Akar2,
- Hueseyin Ince1 and
- Christoph A Nienaber1
© Bozdag-Turan et al.; licensee BioMed Central Ltd. 2012
- Received: 8 March 2012
- Accepted: 9 July 2012
- Published: 9 July 2012
Bone marrow-derived circulating progenitor cells (BM-CPCs) in patients with coronary heart disease are impaired with respect to number and functional activity. However, the relation between the functional activity of BM-CPCs and the number of diseased coronary arteries is yet not known. We analyzed the influence of the number of diseased coronary arteries on the functional activity of BM-CPCs in peripheral blood (PB) in patients with ischemic heart disease (IHD).
The functional activity of BM-CPCs was measured by migration assay and colony forming unit in 120 patients with coronary 1 vessel (IHD1, n = 40), coronary 2 vessel (IHD2, n = 40), coronary 3 vessel disease (IHD3, n = 40) and in a control group of healthy subjects (n = 40). There was no significant difference of the total number of cardiovascular risk factors between IHD groups, beside diabetes mellitus (DM), which was significantly higher in IHD3 group compared to IHD2 and IHD1.
The colony-forming capacity (CFU-E: p < 0.001, CFU-GM: p < 0.001) and migratory response to stromal cell-derived factor 1 (SDF-1: p < 0.001) as well as vascular endothelial growth factor (VEGF: p < 0001) of BM-CPCs were reduced in the group of patients with IHD compared to control group. The functional activity of BM-CPCs was significantly impaired in patients with IHD3 as compared to IHD1 (VEGF: p < 0.01, SDF-1: p < 0.001; CFU-E: p < 0.001, CFU-GM: p < 0.001) and to IHD2 (VEGF: p = 0.003, SDF-1: p = 0.003; CFU-E: p = 0.001, CFU-GM: p = 0.001). No significant differences were observed in functional activity of BM-CPCs between patients with IHD2 and IHD1 (VEGF: p = 0.8, SDF-1: p = 0.9; CFU-E: p = 0.1, CFU-GM: p = 0.1). Interestingly, the levels of haemoglobin AIc (HbAIc) correlated inversely with the functional activity of BM-CPCs (VEGF: p < 0.001, r = −0.8 SDF-1: p < 0.001, r = −0.8; CFU-E: p = 0.001, r = −0.7, CFU-GM: p = 0.001, r = −0.6) in IHD patients with DM.
The functional activity of BM-CPCs in PB is impaired in patients with IHD. This impairment increases with the number of diseased coronary arteries. Moreover, the regenerative capacity of BM-CPCs in ischemic tissue further declines in IHD patients with DM. Furthermore, monitoring the level of BM-CPCs in PB may provide new insights in patients with IHD.
- Circulating progenitor cells
- Migration capacity
- Colony forming capacity
- Ischemic heart disease
- Coronary artery disease
Circulating progenitor cells (CPCs) are primitive bone marrow cells (BMCs), that have the capacity to proliferate, migrate, and differentiate into various mature cell types. [1–3] Furthermore, these cells circulate in peripheral blood, and implicate in neoangiogenesis after tissue ischemia. [4–6] Experimental studies have shown that re-introduction of cytokines such as vascular endothelial growth factor (VEGF), angiopoetin-1, SDF-1, G-CSF, or GM-CSF enhance the mobilization of the BM-CPCs to the ischemic myocardium, augmenting neovascularization. [7, 8] It has been suggested that cardiovascular risk factors (CVRFs) are associated with reduction of functional activity of BM-CPCs in patients with coronary artery disease as well as in healthy men. [9, 10] Moreover, especially diabetes has been shown to reduce numbers and impair functional activity of BM-CPCs. [11–13] However, it is unknown whether the functional activity of BM-CPCs relates to the number of diseased coronary arteries in patients with IHD. In this study, we analyzed the functional activity of BM-CPCs and their relationship with the number of diseased coronary arteries in IHD-patients.
Study protocol and study population
132 IHD patients between 18–80 years of age were screened for inclusion in this study, if they had had a documented MI at least 6 months ago and had left ventricular dysfunction. 12 of 132 patients had to be excluded from the study due to acute coronary syndrom and/or acutely decompensated heart failure. All 120 IHD patients underwent diagnostic cardiac catheterization due to stable angina. We selected a control group of 40 healthy subjects without overt heart disease and/or major cardiovascular risk factors such as diabetes, smoking, hypertension, hypercholesterolemia, and positive family history concerning IHD. All of them had atypical chestpain but no evidence of cardiac ischaemia. Control subjects underwent coronary angiography to rule out ischaemic heart disease within 24 hours after admission. The patients were recruited during diagnostic cardiac catheterization by interventional cardiologist and were separated into 4 groups (I) IHD1; II) IHD2; III) IHD3 and IV) Control group). After this step a peripheral blood sample was taken during cardiac catheterization to measure functional activity and characterization of BM-CPCs before any interventional procedure. A CVRFs score including age > 40 years, male sex, hypertension, diabetes, smoking, positive family history and hypercholesterolaemia was calculated according to Vita et al.  Hypertension was defined as a history of hypertension for >1 year that required the initiation of antihypertensive therapy by the primary physician. Smoking was defined as patients revealing a history of smoking for >2 pack-years and current smoking. Positive family history was defined as documented evidence of coronary artery disease (CAD) in a parent or sibling before 60 years of age. Hypercholesterolaemia was defined as fasting low-density-lipoprotein (LDL) cholesterol levels exceeding 130 mg/dl. Diabetes was defined as the need for oral antidiabetic drug therapy or insulin use.
Exclusion criteria were the presence of acutely decompensated heart failure with a New York Heart Association (NYHA) class of IV, infectious or inflammatory disease, surgery or trauma within 2 months, renal or liver dysfunction, thrombocytopenia, anemia, severe comorbidity and alcohol or drug dependency, history of other severe chronic diseases or cancer, or unwillingness to participate. The study conforms with the principles outlined in the Declaration of Helsinki and was approved by the local ethics committee. Written informed consent was obtained from each patient.
Coronary angiography and left ventriculography
All IHD patients underwent left heart catheterization, left ventriculography and coronary angiography. Cardiac catheterization was performed according to the guidelines for coronary angiography of the American College of Cardiology and the American Heart Association.  Cardiac function was determined by left ventriculography. Cardiac function was evaluated by global EF. Global EF was measured with Quantcor software (Siemens, Erlangen/Germany). The extent of coronary artery disease was scored, by at least two independent interventional cardiologists, as 0 (stenosis < 50 percent), 1 (stenosis of any main coronary artery > 50 percent), 2 (stenosis of two main coronary arteries > 50 percent), and 3 (stenosis of three main coronary arteries > 50 percent).
Phenotypic characterization of BM-CPCs
Phenotypic characterization of BM-CPCs were performed in 5 of 20 ml peripheral blood (PB) for CD34/45+ and CD133/45+ by flow cytometry (EPICS-XL, Beckmann Coulter).
Samples were stained with fluorescein isothiacyanate (FITC) conjugate of a CD45+ antibody (clone J33, Coulter/Immunotech, Marseille/France) that detects all isoforms and glycoforms of the CD45 family, phycoerythrin (PE) conjugate of a CD34+ antibody (clone 581, Coulter/Immunotech, Marseille/France) that detects a class III epitope on all glycoforms of the CD34+ antigen and PE conjugate of a CD133/1+ (Miltenyi Biotec, Bergisch Gladbach/Germany). Control samples were stained with CD45+ FITC and an IgG1 PE (Coulter/Immunotech, Marseille/France) isotype.
For each patient EDTA blood samples were labelled with CD34/45+, CD133/45+, and IgG1/CD45. All tubes were incubated at room temperature in the dark. After incubation, cells were lysed with ammonium chloride, washed with phosphate-buffered saline (PBS). Samples were then stored on ice at 4 °C in dark environment for 20 minutes and analysed by flow cytometry.
Samples were subjected to a 2D side scatter-fluorescence dot plot analysis. After appropriate gating, the concentration of BM-CPCs with low cytoplasmic granularity (low side ward scatter) was quantified and expressed as concentration of cells per million white blood cells.
Isolation and cultivation of BM-CPCs
20 ml peripheral venous blood was taken using a BD Vacutainer CPTTM from each patient. BM-CPCs were isolated by density gradient centrifugation. After 2 washing steps, cells were resuspended in 1 ml EBM2-medium (Cell system). The number of isolated BM-CPCs were determined in a Neubauer chamber.[10, 16]
Assessment of migration assay
A total of 1x106 BM-CPCs were resuspended in 250 μl X-Vivo and placed in the top compartment of a Boyden Chamber. This chamber was placed in a 24-well culture dish contained either only EBM-2 medium or 100 ng/ml stromal cell derived factor-1 (SDF-1) or 100 ng/ml vascular endothelial growth factor (VEGF) in EBM2-medium. After 24 hours of incubation at 37 °C transmigrated cells were counted by 2 independent investigators. [10, 16] Quantitative evaluation of migrated cells to SDF-1 and VEGF were analyzed in comparison to cells without chemokine in blood samples of both groups. Values are expressed as % of migrated cells without chemokine.
Assessment of colony forming unit assay
1x105 in BM-CPCs per ml were seeded in Methocult GF H4435 (Stemcell Technologies). Culture dishes were seeded with 1 ml cell suspension and then incubated at 37 °C. Colony-forming unit erythroid (CFU-E) and CFU-granulocyte/macrophage (CFU-GM) were studied under phase-contrast microscopy and were counted after 14 days of incubation by 2 independent investigators. 
Peripheral blood was collected from patients with IHD and control group on day 1 of admission. Serum creatine phosphokinase (CPK) values (normal range: 24–195 U/l), inflammatory markers such as C - reactive protein (normal range <0.5 mg/dl) and leukocytes (normal range: 4–12 x103/μl) and routine laboratory tests with HbA1C were measured in the study population.
Continuous data are presented as mean ± SD. Comparison of the distributions of a continuous variable between two independent groups was performed using the two-sided nonparametric Mann–Whitney test. The type I error rate α was chosen as 5% and two-sided p-values equal or less 0.05 were interpreted as statistically significant. Some qualitative baseline characteristics were compared using the Fisher's Exact-Test.
Bivariate regression analysis was presented in a graphical form and Pearson's correlation coefficient was obtained.
Statistical significant was accepted, if the corresponding two-sided p-value was smaller or equal to 0.05. Statistical analysis was performed with SPSS for Windows (Version 15.0).
Baseline characteristics of the patients and healthy control subjects
Baseline clinical characterics of the study population
IHD1(n = 40)
IHD 2(n = 40)
IHD 3(n = 40)
Control Group (n=40)
60 ± 15
60 ± 11
64 ± 10
66 ± 10
Cardiovascular Risk Factors % (n)
80 (n = 32)
80 (n = 32)
78 (n = 31)
60 (n = 24)
60 (n = 24)
53 (n = 21)
68 (n = 27)
75 (n = 30)
63 (n = 25)
Positive family history of CAD
40 (n = 16)
35 (n = 14)
20 (n = 8)
20 (n = 8)
60 (n = 24)
p = 0.001
15 (n = 6)
15 (n = 6)
45 (n = 18)
5 (n = 2)
5 (n = 2)
15 (n = 6)
Total number of CVRFs
4.2 ± 0.8
4.3 ± 0.8
4.4 ± 0.9
Infarct-related vessel (LAD/LCX/RCA)
PTCA/Stent at the time of AMI
Ejection fraction (%)
45 ± 10
43 ± 11
40 ± 10
69 ± 9
ACE inhibitor or AT II blocker
Functional activity of BM-CPCs
Impact of DM on the functional activity of BM-CPCs in patients with IHD
In this study we examined the influence of the number of diseased coronary arteries on the functional activity of BM-CPCs in patients with IHD.
Coronary artery disease results from a chronic inflammatory disease of the vascular wall and leads to vessel occlusion and organ damage. [17, 18] Despite intense efforts to determine the pathogenesis of atherosclerosis, this process remains poorly understood. Reports suggest that risk factors and a genetic predisposition together induce inflammatory processes that lead to cell damage and impair regeneration within the vessel wall. [19, 20] Since resident endothelial cells infrequently proliferate,  it has been postulated that there are other sources of vascular replenishment in response to continuous damage . Circulating progenitor cells derived from bone marrow circulate in the peripheral blood and have been implicated in neoangiogenesis after tissue ischemia has occurred. [23–26] BM-CPCs is another population of progenitor cells that has also been shown to have therapeutic potential in the pool of progenitor cells circulating within the blood. BM-CPCs are capable of proliferating and differentiating into endothelial cells and are therefore ideal candidates for vascular regeneration. [27, 28] Experimental and clinical studies suggest that the systemic application or mobilization of stem cells and progenitor cells beneficially influences the repair of endothelial cells after injury and the progression of atherosclerosis. [29–35] Previous studies demonstrate that risk factors for coronary artery disease correlate with number and functional activity of BM-CPCs.  Not only is the quantity of BM-CPCs altered, but their function is also modified by ischemic conditions and therapeutic interventions.  Migration is essential for the stem/progenitor cells to invade the ischemic tissue. SDF-1 and VEGF are both profoundly upregulated in hypoxic tissue [36, 37] and thus represent physiologically relevant chemoattractants for the recruitment of circulating progenitor cells to sites of ischemia. Indeed, intramuscular injection of the chemoattractant chemokine SDF-1 has recently been shown to increase the number of incorporated BM-CPCs and to improve neovascularization in vivo.  Thus, the migratory response toward SDF-1 may indeed play a crucial role for integration of BM-CPCs in ischemic tissue. In addition, the accumulation of cardiovascular risk factors or an increased overall risk is associated with impaired colony forming activity of CPCs in healthy men.  Werner et al.  identified a significant association between increasing numbers and functional activities of BM-CPCs and decreased risk of major cardiovascular event and hospitalization in patients with coronary artery disease. In humans, a small-scale study suggests that there is a higher incidence of restenosis and revascularization in patients with reduced levels of BM-CPCs than in patients with increased numbers. [18, 39] Recently we showed that Intracoronary transplantation of autologous BMCs may enhance and prolong the mobilisation as well as functional activity of BM-CPCs in PB in patients with ischemic heart disease and this might increase the regenerative potency in IHD. [40–42] Moreover, the mobilization of CD34+ and CD133+ BM-CPCs is further impaired by DM in patients with IHD. [43, 44] However, it is unknown whether the functional activity of BM-CPCs relates with the number of diseased coronary arteries in patients with IHD. We demonstrated in our study, that the functional activity of BM-CPCs was significantly impaired in patients with IHD3 compared to IHD2 and IHD1. Diabetes mellitus is associated with both an increased risk of atherosclerotic disease and poor outcome after vascular occlusion. The clinical severity of vascular occlusive disease in diabetics has in part been attributed to impaired collateral vessel development . Extensive studies have shown that the numbers of circulating angiogenic cells are significantly lower in type II diabetes, and their angiogenic potential is also dramatically diminished. These cells display defective adhesion to the endothelium, reduced proliferation rate, and impaired ability to create new vascular structures. [11, 12, 46] On the basis of these findings, it is tempting to speculate that the decrease of functional activity of BM-CPCs by DM leads to progression of atherosclerosis and increases the number of diseased coronary arteries in patients with IHD. In line with this hypothesis we observed in our study a significant higher incidence of DM in patients with IHD3 compared to IHD2 and IHD1. Furthermore, we demonstrated that the functional activity of BM-CPCs inversely correlated with the level of HbA1c in IHD patients with DM. The functional activity of BM-CPCs in DM patients with HbA1c > 7% was significantly reduced compared to DM patients with HbA1c <7%. Recent studies have shown that the PPARϒ agonist pioglitazone treatment increases the number and function of BM-CPCs in type 2 DM patients with coronary artery disease. [47, 48] Improved levels of HbA1c by pharmacological therapy may lead to increase of BM-CPCs mobilization and functional activity and thereby may enhance the vascular regeneration in IHD patients with DM.
In the present study we could demonstrate that the functional activity of BM-CPCs was impaired in patients with IHD. This impairment correlates with increase of the number of diseased coronary arteries. Moreover, the regenerative capacity in ischemic tissue of BM-CPCs further declines in IHD patients with DM.
We thank Andrea Thesenvitz for the technical assistance.
- Luttun A, Carmeliet G, Carmeliet P: Vascular progenitors: from biology to treatment. Trends Cardiovasc Med. 2002, 12: 88-96. 10.1016/S1050-1738(01)00152-9.View ArticlePubMedGoogle Scholar
- Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S: Endothelial progenitor cells, new hope for a broken heart. Circulation. 2003, 107: 3093-3100. 10.1161/01.CIR.0000074242.66719.4A.View ArticlePubMedGoogle Scholar
- Deschaseaux F, Pontikoglou C, Sensébé L: Bone regeneration: the stem/progenitor cells point of view. J Cell Mol Med. 2010, 14: 103-115. 10.1111/j.1582-4934.2009.00878.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Timmermans F, Plum J, Yöder MC, Ingram DA, Vandekerckhove B, Case J: Endothelial progenitor cells: identity defined?. J Cell Mol Med. 2010, 13: 87-102.View ArticleGoogle Scholar
- Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999, 85: 221-228. 10.1161/01.RES.85.3.221.View ArticlePubMedGoogle Scholar
- Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T: Ischemia-and cytokine-induced mobilization of bone-marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999, 5: 434-438. 10.1038/7434.View ArticlePubMedGoogle Scholar
- Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH, Hackett NR, Quitoriano MS, Crystal RG, Rafii S, Moore MA: Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoetic progenitor and stem cells. Blood. 2001, 97: 3354-3360. 10.1182/blood.V97.11.3354.View ArticlePubMedGoogle Scholar
- Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, Rafii S: Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and aniopoietin. Ann NY Acad Sci. 2001, 938: 36-47.View ArticlePubMedGoogle Scholar
- Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003, 348: 593-600. 10.1056/NEJMoa022287.View ArticlePubMedGoogle Scholar
- Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S: Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001, 89: E1-E7. 10.1161/hh1301.093953.View ArticlePubMedGoogle Scholar
- Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC: Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002, 106: 2781-2786. 10.1161/01.CIR.0000039526.42991.93.View ArticlePubMedGoogle Scholar
- Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, Grego F, de Kreutzenberg Vigili S, Tiengo A, Agostini C, Avogaro A: Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol. 2006, 26: 2140-2146. 10.1161/01.ATV.0000237750.44469.88.View ArticlePubMedGoogle Scholar
- Li M, Takeneka H, Asai J, Ibusuki K, Mizukami Y, Maruyama K, Yoon YS, Wecker A, Luedemann C, Eaton E, Silver M, Thorne T, Losordo DW: Endothelial progenitor thrombospondin-1 mediates diabetes induced delay in reendothelialization following arterial injury. Circ Res. 2006, 98: 697-704. 10.1161/01.RES.0000209948.50943.ea.View ArticleGoogle Scholar
- Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990, 81: 491-497. 10.1161/01.CIR.81.2.491.View ArticlePubMedGoogle Scholar
- Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JA, Nissen SE, Pepine CJ, Watson RM, Ritchie JL, Gibbons RJ, Cheitlin MD, Gardner TJ, Garson A, Russell RO, Ryan TJ, Smith SC: ACC/AHA guidelines for coronary angiography: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography): developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 1999, 33: 1756-1824. 10.1016/S0735-1097(99)00126-6.View ArticlePubMedGoogle Scholar
- Heeschen C, Lehman R, Honold J, Assmus B, Aicher A, Walter DH, Martin H, Zeiher AM, Dimmeler S: Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation. 2004, 109: 1615-1622. 10.1161/01.CIR.0000124476.32871.E3.View ArticlePubMedGoogle Scholar
- Ross R: Atherosclerosis an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.View ArticlePubMedGoogle Scholar
- Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G: Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes. N Engl J Med. 2005, 353: 999-1007. 10.1056/NEJMoa043814.View ArticlePubMedGoogle Scholar
- Choy JC, Granville DJ, Hunt DW, McManus BM: Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol. 2001, 33: 1673-1690. 10.1006/jmcc.2001.1419.View ArticlePubMedGoogle Scholar
- Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S: Vascular trauma induces rapid but transient mobilization of VEGFR2(+) AC133(+) endothelial precursor cells. Circ Res. 2001, 88: 167-174. 10.1161/01.RES.88.2.167.View ArticlePubMedGoogle Scholar
- Schwartz SM, Benditt EP: Clustering of replicating cells in aortic endothelium. Proc Natl Acad Sci U S A. 1976, 73: 651-653. 10.1073/pnas.73.2.651.View ArticlePubMedPubMed CentralGoogle Scholar
- Opden Buijs J, Musters M, Verrips T, Post JA, Braam B, van Riel N: Mathematical modeling of vascular endothelial layer maintenance: the role of endothelial cell division, progenitor cell homing, and telomere shortening. Am J Physiol Heart Circ Physiol. 2004, 287: H2651-H2658. 10.1152/ajpheart.00332.2004.View ArticleGoogle Scholar
- Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997, 275: 964-967. 10.1126/science.275.5302.964.View ArticlePubMedGoogle Scholar
- Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T: Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000, 97: 3422-3427.View ArticlePubMedPubMed CentralGoogle Scholar
- Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM, Asahara T: Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001, 103: 634-637. 10.1161/01.CIR.103.5.634.View ArticlePubMedGoogle Scholar
- Rafii S, Lyden D: Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003, 9: 702-712. 10.1038/nm0603-702.View ArticlePubMedGoogle Scholar
- Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schäfer B, Hossfeld DK, Fiedler W: In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000, 95: 3106-3112.PubMedGoogle Scholar
- Gunsilius E, Duba HC, Petzer AL, Kähler CM, Gastl GA: Contribution of endothelial cells of hematopoietic origin to blood vessel formation. Circ Res. 2001, 88: E1-10.1161/01.RES.88.1.e1.View ArticlePubMedGoogle Scholar
- Kong D, Melo LG, Gnecchi M, Zhang L, Mostoslavsky G, Liew CC, Pratt RE, Dzau VJ: Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation. 2004, 110: 2039-2046. 10.1161/01.CIR.0000143161.01901.BD.View ArticlePubMedGoogle Scholar
- Nowak G, Karrar A, Holmen C, Nava S, Uzunel M, Hultenby K, Sumitran-Holgersson S: Expression of vascular endothelial growth factor receptor-2 or tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization. Circulation. 2004, 110: 3699-3707. 10.1161/01.CIR.0000143626.16576.51.View ArticlePubMedGoogle Scholar
- Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, Priller J, Laufs K, Ghaeni L, Milosevic M, Böhm M, Nickenig G: Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation. 2003, 107: 3059-3065. 10.1161/01.CIR.0000077911.81151.30.View ArticlePubMedGoogle Scholar
- Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, Isner JM: Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002, 105: 3017-3024. 10.1161/01.CIR.0000018166.84319.55.View ArticlePubMedGoogle Scholar
- Werner N, Priller J, Laufs U, Endres M, Böhm M, Dirnagl U, Nickenig G: Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition. Arterioscler Thromb Vasc Biol. 2002, 22: 1567-1572. 10.1161/01.ATV.0000036417.43987.D8.View ArticlePubMedGoogle Scholar
- Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, Nickenig G: Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res. 2003, 93: e17-e24. 10.1161/01.RES.0000083812.30141.74.View ArticlePubMedGoogle Scholar
- Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, Pippen AM, Annex BH, Dong C, Taylor DA: Aging, progenitor cell exhaustion, and atherosclerosis. Circulation. 2003, 108: 457-463. 10.1161/01.CIR.0000082924.75945.48.View ArticlePubMedGoogle Scholar
- Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA: Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Eng J Med. 2000, 342: 626-633. 10.1056/NEJM200003023420904.View ArticleGoogle Scholar
- Pilarisetti K, Gupta SK: Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1) 1:SDF-1 alpha mRNA is selectively induced in rat model of myocardial infarction. Inflammation. 2001, 25: 293-300. 10.1023/A:1012808525370.View ArticleGoogle Scholar
- Yamaguchi J, Kussano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T: Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003, 107: 1322-1328. 10.1161/01.CIR.0000055313.77510.22.View ArticlePubMedGoogle Scholar
- George J, Herz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A, Michowitz Y, Miller H, Keren G: Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol. 2003, 23: e57-e60. 10.1161/01.ATV.0000107029.65274.db.View ArticlePubMedGoogle Scholar
- Turan RG, Bozdag-Turan I, Ortak J, Akin I, Kische S, Schneider H, Turan CH, Rehders TC, Rauchhaus M, Kleinfeldt T, Adolph E, Brehm M, Yokus S, Steiner S, Sahin K, Nienaber CA, Ince H: Improved mobilisation of the CD34+ and CD133+ bone marrow derived circulating progenitor cells by freshly isolated intracoronary bone marrow cells transplantation in patients with ischemic heart disease. Stem Cell and Dev. 2011, 20 (9): 1491-1501. 10.1089/scd.2010.0373.View ArticleGoogle Scholar
- Turan RG, Bozdag-Turan I, Ortak J, Kische S, Akin I, Schneider H, Turan CH, Rehders TC, Rauchhaus M, Kleinfeldt T, Belu C, Brehm M, Yokus S, Steiner S, Sahin K, Nienaber CA, Ince H: Improved functional activity of bone marrow derived circulating progenitor cells after intra coronary freshly isolated bone marrow cells transplantation in patients with ischemic heart disease. Stem Cell Rev. 2011, 7 (3): 646-656. 10.1007/s12015-010-9220-8.View ArticlePubMedPubMed CentralGoogle Scholar
- Turan RG, Bozdag-Turan I, Turan CH, Ortak J, Akin I, Kische S, Schneider H, Rauchhaus M, Rehders TC, Kleinfeldt T, Belu C, Amen S, Hermann T, Yokus S, Brehm M, Steiner S, Chatterjee T, Sahin K, Nienaber CA, Ince H: Enhanced mobilisation of the bone marrow derived circulating progenitor cells by intracoronary freshly isolated bone marrow cells transplantation in patients with acute myocardial infarction. J Cell Mol Med. 2012, 16 (4): 852-864. 10.1111/j.1582-4934.2011.01358.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Turan RG, Turan CH, Bozdag-Turan I, Ortak J, Akin I, Kische S, Schneider H, Kleinfeldt T, Rehders TC, Rauchhaus M, Adolph E, Amen S, Hermann T, Yokus S, Brehm M, Steiner S, Sahin K, Nienaber CA, Ince H: Impaired Mobilization of CD133(+) Bone Marrow-Derived Circulating Progenitor Cells With an Increased Number of Diseased Coronary Arteries in Ischemic Heart Disease Patients With Diabetes. Circ J. 2011, 75 (11): 2635-2641. 10.1253/circj.CJ-10-1284.View ArticlePubMedGoogle Scholar
- Bozdag-Turan I, Turan RG, Turan CH, Ludovicy S, Akin I, Kische S, Arsoy NS, Schneider H, Ortak J, Rehders T, Hermann T, Paranskaya L, Kohlschein P, Bastian M, Ulus AT, Sahin K, Ince H, Nienaber CA: Relation between the frequency of CD34+ bone marrow derived circulating progenitor cells and the number of diseased coronary arteries in patients with myocardial ischemia and diabetes. Cardiovasc Diabetol. 2011, 10: 107-10.1186/1475-2840-10-107.View ArticlePubMedPubMed CentralGoogle Scholar
- Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinç H, Ergin A: Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 1999, 99: 2239-2242. 10.1161/01.CIR.99.17.2239.View ArticlePubMedGoogle Scholar
- Caballero S, Sengupta N, Afzal A, Chang KH, Li Calzi S, Guberski DL, Kern TS, Grant MB: Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes J. 2007, 56: 960-967. 10.2337/db06-1254.View ArticleGoogle Scholar
- Werner C, Kamani CH, Gensch C, Böhm M, Laufs U: The peroxisome proliferator-activated receptor-y agonist pioglitazone increases number and function of endothelial progenitor cells in patients with Coronary Artery Disease and normal glucose tolerance. Diabetes J. 2007, 56: 2609-2615. 10.2337/db07-0069.View ArticleGoogle Scholar
- Makino H, Okada S, Nagumo A, Sugisawa T, Miyamoto Y, Kishimoto I, Akie TK, Soma T, Taguchi A, Yoshimasa Y: Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients. Diabetes Res Clin Pract. 2008, 81: 327-330. 10.1016/j.diabres.2008.05.012.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.